Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

44.85 +0.70 (+1.59%)
Streaming Delayed Price Updated: 9:49 AM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
The Ultimate Biotech Stock to Buy With $50 Right Now ↗
This innovative drugmaker still has plenty of upside potential. 
Via The Motley Fool
News headline image
EXELIXIS INC (NASDAQ:EXEL) Identified as a Quality Value Stock by Fundamental Screening ↗
Exelixis (EXEL) presents a strong value investment case with low P/E ratios, zero debt, robust profitability, and solid growth in the biotech sector. 
Via Chartmill
News headline image
EXELIXIS INC (NASDAQ:EXEL) Stands Out as an Affordable Growth Stock ↗
Discover EXELIXIS INC (EXEL), an affordable growth stock with strong financials, impressive earnings, and a discounted valuation in the biotech sector. 
Via Chartmill
News headline image
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years ↗
Both should have significant catalysts by the end of the decade. 
Via The Motley Fool
News headline image
17 Analysts Have This To Say About Exelixis ↗
 
Via Benzinga
News headline image
Peering Into Exelixis's Recent Short Interest ↗
 
Via Benzinga
News headline image
Is the Market Bullish or Bearish on Exelixis? ↗
 
Via Benzinga
News headline image
EXELIXIS INC (NASDAQ:EXEL) Emerges as a Top Undervalued Stock with Strong Fundamentals ↗
EXELIXIS (EXEL) emerges as a top value stock with strong fundamentals: undervalued, zero debt, high profitability, and solid growth in the biotech sector. 
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
News headline image
Exelixis Inc (NASDAQ:EXEL) Embodies the Affordable Growth Investment Strategy ↗
Exelixis (EXEL) offers affordable growth with strong oncology revenue, high profitability, a robust balance sheet, and attractive valuation metrics. 
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
News headline image
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
News headline image
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
From Exelixis, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
From Exelixis, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
News headline image
EXELIXIS INC (NASDAQ:EXEL) Emerges as a Compelling Value Investment Opportunity ↗
Exelixis (EXEL) is a strong value investing candidate, trading below intrinsic value with a solid financial profile, high profitability, and strong growth prospects. 
Via Chartmill
News headline image
EXELIXIS INC (NASDAQ:EXEL) Emerges as a Top Growth at a Reasonable Price (GARP) Stock ↗
EXELIXIS INC (EXEL) is a top GARP stock with strong growth, high profitability, and a reasonable valuation, making it a compelling investment opportunity. 
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
News headline image
Exelixis Inc (NASDAQ:EXEL): A Strong Growth Stock with Bullish Technical Setup ↗
Exelixis (EXEL) is a strong growth stock with solid fundamentals—17.5% revenue growth, high profitability, and no debt—plus a bullish technical setup, signaling a potential breakout opportunity. 
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
News headline image
The Analyst Verdict: Exelixis In The Eyes Of 19 Experts ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
News headline image
Exelixis EXEL Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio? ↗
Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidance cuts. 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.